Product Description
a novel, investigational maturation inhibitor for the treatment of HIV (Sourced from: https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv/)
Mechanisms of Action: HIV Maturation Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| A Phase 2b Dose-Range Finding Clinical Trial in HIV-1 Infected Treatment-Naive Adults | P2 |
Completed |
HIV Infections |
2023-05-29 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| DYNAMIC | P2 |
Completed |
HIV Infections |
2023-03-08 |
2025-05-06 |
Treatments|Trial Status |